Bad cholesterol

Companies Merck & Co. Inc. and Schering-Plough Corp were jointly develop Zetia, which includes the active substance ezetimib. The new medicine can prevent the entry of cholesterol in cells of the body. Clinical trials have shown that the substance reduces the content of cholesterol by 18%. When using the same Zetii љв combination with other drugs called new drug can reduce the concentration of cholesterol even further to 18%.

Currently substances, decreases the concentration of cholesterol, causing the explosion of interest of researchers with great respect, the incidence of cardiovascular disease worldwide. Estimated that the market for such products is growing steadily and reached 7-9 billion U.S. dollars, and by 2007 the ninth year will reach 30 billion. Therefore, many the world's largest biotechnology companies have to unite together to put their products on the market. In the case of Zetiey, the drug was first примененљ company Schering-Plough Pharmaceuticals, together with Merck later efforts to co-margeking .